PAHC vs. BMY
PAHC (Phibro Animal Health Corporation) and BMY (Bristol-Myers Squibb Company) are both stocks. Both are in the Healthcare sector — PAHC in Drug Manufacturers - Specialty & Generic, BMY in Drug Manufacturers - General. Over the past 10 years, PAHC returned 7.38%/yr vs 0.97%/yr for BMY. At a 0.24 correlation, their price movements are largely independent.
Performance
PAHC vs. BMY - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, PAHC achieves a -15.51% return, which is significantly lower than BMY's 4.23% return. Over the past 10 years, PAHC has outperformed BMY with an annualized return of 7.38%, while BMY has yielded a comparatively lower 0.97% annualized return.
PAHC
- 1D
- 2.72%
- 1M
- -5.31%
- YTD
- -15.51%
- 6M
- -16.36%
- 1Y
- 28.20%
- 3Y*
- 35.64%
- 5Y*
- 4.58%
- 10Y*
- 7.38%
BMY
- 1D
- -0.95%
- 1M
- -7.50%
- YTD
- 4.23%
- 6M
- 2.77%
- 1Y
- 22.79%
- 3Y*
- -0.96%
- 5Y*
- 0.15%
- 10Y*
- 0.97%
PAHC vs. BMY - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
PAHC Phibro Animal Health Corporation | -15.51% | 80.76% | 86.30% | -10.42% | -32.33% | 7.28% | -20.09% | -21.31% | -3.00% | 15.75% |
BMY Bristol-Myers Squibb Company | 4.23% | 0.11% | 15.81% | -26.14% | 18.98% | 2.88% | 0.41% | 27.74% | -12.90% | 7.71% |
Correlation
The correlation between PAHC and BMY is 0.27, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.27 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.19 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.22 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.22 |
Correlation (All Time) Calculated using the full available price history since Apr 11, 2014 | 0.24 |
Fundamentals
PAHC:
$1.29B
BMY:
$112.39B
PAHC:
$2.33
BMY:
$3.57
PAHC:
13.47
BMY:
15.42
PAHC:
0.03
BMY:
0.88
PAHC:
0.85
BMY:
2.31
PAHC:
3.56
BMY:
5.60
PAHC:
$1.50B
BMY:
$48.48B
PAHC:
$488.12M
BMY:
$33.33B
PAHC:
$219.25M
BMY:
$13.34B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
PAHC vs. BMY — Risk / Return Rank
PAHC
BMY
PAHC vs. BMY - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Phibro Animal Health Corporation (PAHC) and Bristol-Myers Squibb Company (BMY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| PAHC | BMY | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.37 | ||
| Sortino ratioReturn per unit of downside risk | -0.34 | ||
| Omega ratioGain probability vs. loss probability | 1.15 | 1.16 | -0.01 |
| Calmar ratioReturn relative to maximum drawdown | 0.54 | 1.83 | -1.28 |
| Martin ratioReturn relative to average drawdown | 1.59 | 4.11 | -2.52 |
Loading charts...
Drawdowns
PAHC vs. BMY - Drawdown Comparison
The maximum PAHC drawdown since its inception was -79.62%, which is greater than BMY's maximum drawdown of -72.03%. Use the drawdown chart below to compare losses from any high point for PAHC and BMY.
Loading charts...
Drawdown Indicators
| PAHC | BMY | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -79.62% | -72.03% | -7.59% |
Max Drawdown (1Y)Largest decline over 1 year | -52.13% | -12.53% | -39.60% |
Max Drawdown (3Y)Largest decline over 3 years | -52.13% | -36.02% | -16.11% |
Max Drawdown (5Y)Largest decline over 5 years | -65.63% | -47.67% | -17.96% |
Max Drawdown (10Y)Largest decline over 10 years | -79.62% | -47.67% | -31.95% |
Current DrawdownCurrent decline from peak | -47.14% | -20.85% | -26.29% |
Average DrawdownAverage peak-to-trough decline | -39.01% | -22.37% | -16.64% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 17.81% | 5.56% | +12.25% |
Volatility
PAHC vs. BMY - Volatility Comparison
Phibro Animal Health Corporation (PAHC) has a higher volatility of 17.22% compared to Bristol-Myers Squibb Company (BMY) at 8.51%. This indicates that PAHC's price experiences larger fluctuations and is considered to be riskier than BMY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| PAHC | BMY | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 17.22% | 8.51% | +8.71% |
Volatility (6M)Calculated over the trailing 6-month period | 49.16% | 18.00% | +31.16% |
Volatility (1Y)Calculated over the trailing 1-year period | 58.87% | 26.98% | +31.89% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 47.43% | 24.08% | +23.35% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 44.61% | 25.30% | +19.31% |
Dividends
PAHC vs. BMY - Dividend Comparison
PAHC's dividend yield for the trailing twelve months is around 1.53%, less than BMY's 4.55% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
BMY Bristol-Myers Squibb Company | 4.55% | 4.60% | 4.24% | 4.44% | 3.00% | 2.36% | 3.69% | 2.55% | 3.08% | 2.55% | 1.95% | 2.17% |
PAHC Phibro Animal Health Corporation | 1.53% | 1.28% | 2.29% | 4.15% | 3.58% | 2.35% | 2.47% | 1.93% | 1.31% | 1.19% | 1.37% | 1.33% |
Financials
PAHC vs. BMY - Financials Comparison
This section allows you to compare key financial metrics between Phibro Animal Health Corporation and Bristol-Myers Squibb Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
PAHC vs. BMY - Profitability Comparison
PAHC - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Phibro Animal Health Corporation reported a gross profit of 125.68M and revenue of 383.54M. Therefore, the gross margin over that period was 32.8%.
BMY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Bristol-Myers Squibb Company reported a gross profit of 8.07B and revenue of 11.49B. Therefore, the gross margin over that period was 70.2%.
PAHC - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Phibro Animal Health Corporation reported an operating income of 44.65M and revenue of 383.54M, resulting in an operating margin of 11.6%.
BMY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Bristol-Myers Squibb Company reported an operating income of 3.27B and revenue of 11.49B, resulting in an operating margin of 28.5%.
PAHC - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Phibro Animal Health Corporation reported a net income of 24.02M and revenue of 383.54M, resulting in a net margin of 6.3%.
BMY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Bristol-Myers Squibb Company reported a net income of 2.68B and revenue of 11.49B, resulting in a net margin of 23.3%.
Frequently Asked Questions
PAHC and BMY have a correlation of 0.27, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
PAHC has higher volatility (17.22%) compared to BMY (8.51%). In terms of maximum drawdown, PAHC dropped -79.62% vs BMY's -72.03%.
BMY currently has the higher Sharpe Ratio (0.85 vs 0.48), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for PAHC and BMY
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer